News
Public · Published
Guggenheim maintains Buy rating on ArriVent BioPharma, $30 price target
Guggenheim maintained a Buy rating on ArriVent BioPharma with a $30 price target, implying 95.3% upside from the October 26 close of $15.36. The firm raised its probability of success for ARR-217 in metastatic colorectal cancer to 45% from 20%.
Published:
Updated:
What happened
Guggenheim maintained a Buy rating on ArriVent BioPharma with a $30 price target, implying 95.3% upside from the October 26 close of $15.36. The firm raised its probability of success for ARR-217 in metastatic colorectal cancer to 45% from 20%.
Confirmed
Global impact / market context
A higher probability of success means Guggenheim now assigns more value to ARR-217, a drug candidate, which lifts its valuation model and price target. Because the $30 target sits well above the recent close, the note signals the analyst sees more upside in the shares.
Analyst inference
Other analysts recently reiterated Buy ratings on the stock, with price targets from $18 to $29 over the past 30 days. Guggenheim's $30 target sits at the top of that range, suggesting its view is more optimistic than peers after the early trial data.
Analyst inference
What to watch
- The confirmed objective response rate of 38% at the 6 mg/kg dose for ARR-217 is the key early efficacy result, and investors will watch whether it holds up as more patients are treated. Confirmed
- Guggenheim's raised 45% probability of success for ARR-217 in metastatic colorectal cancer is a model assumption, not a reported outcome, so future trial updates could push that estimate up or down. Proposed
- A higher modeled success probability can raise projected future revenue from ARR-217, which may support the stock price and shape how investors position shares relative to peers' targets. Analyst inference
Evidence
- Original source link unavailable